An update on ABO incompatible hematopoietic progenitor cell transplantation

Area of Science:

• Hematology
• Transfusion Medicine
• Immunology

Background:

• Hematopoietic progenitor cell (HPC) transplantation is a key treatment for hematologic malignancies.
• ABO incompatibility (ABOi) occurs in a significant percentage of allogeneic HPC transplants.
• ABOi classifications include major, minor, and bidirectional, each with distinct implications.

Purpose of the Study:

• To review the challenges associated with ABO incompatible HPC transplantation.
• To focus on the critical roles of laboratory and transfusion medicine services in managing ABOi.
• To emphasize the importance of inter-service communication for patient safety.

Main Methods:

• This is a review article, synthesizing existing knowledge.
• The review focuses on adverse events and management strategies.
• Emphasis is placed on laboratory and transfusion medicine aspects.

Main Results:

• Major adverse events of ABOi HPC transplantation include hemolysis, pure red cell aplasia, and delayed engraftment.
• ABOi transplantation requires specialized handling in HPC processing and transfusion services.
• Effective communication between clinical, lab, and transfusion teams is essential.

Conclusions:

• ABO incompatible HPC transplantation necessitates a multidisciplinary approach.
• Laboratory and transfusion medicine services play a pivotal role in mitigating ABOi risks.
• Proactive communication and standardized protocols are crucial for successful ABOi HPC transplantation outcomes.